Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists

in European Journal of Endocrinology

The endocannabinoid system has emerged as a significant player in the control of energy balance and metabolism, through its direct central and peripheral effects, as well as via its interaction with other appetite-regulating pathways. There is mounting evidence that the endocannabinoid system is overactive in obesity and were it possible to safely dampen-down the elevated endocannabinoid tone, lipid and carbohydrate profiles could be improved and weight loss induced. The series of randomised clinical trials showed reproducible beneficial effects on weight, HbA1c and lipid parameters, in addition to other cardiovascular risk factors. However, to date, clinical developments have been halted because of psychiatric side effects. Although recent evidence has highlighted the importance of an appetite-independent, peripheral mode of action, it is still unclear whether selectively blocking the peripheral system could potentially solve the problem of the central side effects, which thus far has led to the demise of the cannabinoid antagonists as useful pharmaceuticals. In this concise review, we summarise the data on the metabolic effects of the cannabinoid pathway and its antagonists.

Abstract

The endocannabinoid system has emerged as a significant player in the control of energy balance and metabolism, through its direct central and peripheral effects, as well as via its interaction with other appetite-regulating pathways. There is mounting evidence that the endocannabinoid system is overactive in obesity and were it possible to safely dampen-down the elevated endocannabinoid tone, lipid and carbohydrate profiles could be improved and weight loss induced. The series of randomised clinical trials showed reproducible beneficial effects on weight, HbA1c and lipid parameters, in addition to other cardiovascular risk factors. However, to date, clinical developments have been halted because of psychiatric side effects. Although recent evidence has highlighted the importance of an appetite-independent, peripheral mode of action, it is still unclear whether selectively blocking the peripheral system could potentially solve the problem of the central side effects, which thus far has led to the demise of the cannabinoid antagonists as useful pharmaceuticals. In this concise review, we summarise the data on the metabolic effects of the cannabinoid pathway and its antagonists.

Introduction

The endocannabinoid system is a complex physiologic system that is highly relevant in the control of energy balance and metabolism (1). Upon stimulation, it increases food intake and weight gain, promotes lipogenesis and impairs glucose tolerance (2). There is growing evidence that the endocannabinoid system is overactive in obesity (3, 4), and thus targeting and suppressing the system could result in a potential pathway by which to treat obesity, type 2 diabetes and the metabolic syndrome. Despite the early promising results of the cannabinoid antagonists, the drug's side effect profile regarding depression and suicidal risk has been deemed unsafe, and thus, to date, all preparations have been withdrawn from trials or clinical practice. Here, we discuss the discovery, physiology and mechanism of action of the endocannabinoid system, along with its potential for manipulation in the treatment of obesity.

The discovery and physiology of the endocannabinoids

The plant Cannabis sativa has been used to promote caloric intake by enhancing appetite for hundreds of years (5, 6). Despite knowledge of its medical benefits for centuries, it was not until 1964 that the psychoactive component of cannabis was isolated as Δ-9-tetrahydrocannabinol (7), which subsequently led to the discovery and cloning of two specific Gi/o protein-coupled cannabinoid receptors, CB1 (8) and CB2 (9). Both receptors are expressed in the CNS, as well as in peripheral tissues. CB1 was found to be one of the most prevalent G protein-coupled receptors in the mammalian brain, while CB2 was shown to have prominent roles in immune and haematopoietic cells, as well as osteoblasts and osteoclasts (10, 11, 12, 13). The discovery of specific cannabinoid receptors implied that endogenous ligands capable of activating these receptors must exist. Anandamide and 2-arachidonoylglycerol (2-AG) are the two most widely studied ‘endocannabinoids’. They are not stored in vesicles like other neurotransmitters, but produced on demand by Ca2+-induced enzymatic cleavage from phospholipid precursors (14). CB1 receptors are often localised on pre-synaptic neurons, which suggest retrograde signal transmission (15) (Fig. 1), whereby the endocannabinoids usually act to reduce neuronal excitability via inhibitory effects on voltage-gated Ca2+ channels and the activation of K+ channels (16) (Fig. 2). In addition to CB1 and CB2, several other receptors were shown to be targets of endocannabinoids, including the transient receptor potential cation channel, subfamily V, member 1 (TPRV1) (17), a novel orphan cannabinoid receptor GPR55 (18) and additional unidentified endothelial and cardiac receptors, which may mediate endocannabinoid-induced cardiovascular effects (19, 20).

Figure 1

Download Figure

Figure 1

Upon stimulation of the postsynaptic cell, an influx of intracellular calcium results in the activation of N-acylphosphatidylethamolamine hydrolysing phospholipase D (NAPE–PLD) and diacyl–glycerol lipase (DAGL-α and -β) and release of endocannabinoids (e.g. anandamide (ANA) or 2-arachidonoylglycerol (2-AG)) from the postsynaptic terminal. The endocannabinoid crosses the synaptic cleft and binds to its receptor on the presynaptic terminal. Cannabinoid receptor activation often results in blocked neurotransmitter release from the presynaptic neuron. The endocannabinoids are taken up by the postsynaptic cell via a method of unspecified transport (green crescents) and are finally inactivated and degraded by fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL) (83, 84).

Citation: European Journal of Endocrinology 161, 5; 10.1530/EJE-09-0511

Figure 2

Download Figure

Figure 2

Cannabinoid receptor activation often leads to reduced cellular neurotransmission by blocking Ca2+ entry, via hyperpolarisation, as a result of K+ channel activation, or by reduced cAMP generation.

Citation: European Journal of Endocrinology 161, 5; 10.1530/EJE-09-0511

The cannabinoids have wide ranging effects on various systems including mood, cognition and reward, immune, gastrointestinal and reproduction, sleep, neuroprotection, bone and cardiovascular function, in addition to appetite, lipid and carbohydrate metabolism (15). The orexigenic effect of the endocannabinoids is mediated via activation of AMP-activated protein kinase (AMPK) (21, 22, 23). AMPK plays a central role in the control of energy homeostasis both at an individual cellular level and that of the whole body via its appetite-stimulating effects in the hypothalamus. It can sense the cellular ‘energy status’ and upon activation causes the cell to switch from ATP consumption to ATP production. AMPK is known to be influenced by various stimuli such as leptin, ghrelin, adiponectin and α-melanocortin-stimulating hormone, as well as metformin and glitazones (24).

Interaction with other hormones and systems

It seems that cannabinoids interact with a number of hormonal systems and possibly mediate their effects. Data for heterodimerisation of the receptor with the orexin (25), type 2 dopamine (26) and opioid receptors (27) have been shown, and possible other partners have been suggested, such as the ghrelin receptor (28) (Table 1).

Table 1

Interaction with other hormones and systems.

Interacting partnersEffectReference
Leptin• Leptin reduces endocannabinoid levels in the hypothalamus(30, 31, 32, 33)
• Leptin-deficient animals reduce food intake in response to a CB1 antagonist
• Leptin-deficient animals have high endocannabinoid levels
• Anorexia nervosa patients have high circulating endocannabinoid levels
Ghrelin• Ghrelin increases endocannabinoid levels in the hypothalamus(28)
• Intact CB1 is necessary for ghrelin appetite and AMPK effects in the hypothalamus
Adiponectin• CB1 antagonist increases adiponectin levels(30, 34)
• The beneficial effects of CB1 antagonist are partly (but not fully) via adiponectin
NPY, αMSH• Anandamide increases hypothalamic neuropeptide Y, an effect inhibited by cannabinoid antagonists(35, 36)
• α-MSH and the cannabinoid system have been shown to decrease food intake  synergistically
Orexin• Orexin receptor, OX1R, was shown to heterodimerise with the CB1 receptor, leading to increased orexin effects(25, 37)
Glucocorticoids• Glucocorticoids release endocannabinoids in the hypothalamus(38, 39, 82)
Neurotransmitters• The endocannabinoid system influences the release of various neurotransmitters,  including GABA, noradrenaline, dopamine, glutamate and acetylcholine(29, 40, 41)
• A direct interaction of dopamine receptors and CB1 has been suggested

Mode of action: central versus peripheral

Initially, it was thought that the endocannabinoid system acted solely centrally through its effects on appetite and food intake. In support of this, the CB1 receptor is widely prevalent centrally (8, 42), and central administration of anandamide into the ventromedial nucleus causes hyperphagia in rats (22). However, the endocannabinoids not only act centrally but also peripherally in the control of energy balance and metabolism. CB1 receptors have been found peripherally on the nerve terminals of gastrointestinal tract neurons (43), liver (44), skeletal muscle (45), pancreas (46) and in adipose tissue (47). Upon pair feeding of CB1 knockout (CB1−/−) mice with normal littermates, wild-type mice gained weight, while the CB1−/− did not, despite the same caloric intake (48). Similarly, chronic injection of a CB1 receptor antagonist in obese rodents caused significant weight loss, which was sustained despite only a transient decrease in caloric intake (49). A human study showed an increase in caloric intake and weight gain in volunteers who smoked cannabis when compared with controls (50); interestingly, although the weight of the participants continued to increase throughout the 3-week study, the increased food intake subsided after just a few days. This suggests that the cannabinoids increase weight by methods other than solely stimulating appetite. In addition, food deprivation leads to a sevenfold increase in intestinal levels of anandamide, and this effect is reversed upon refeeding. When the neurotoxin capsaicin was used to destroy the sensory afferent fibres of the gut, the effects of peripherally administered anandamide were abolished. This is supportive of a peripheral mechanism of action, whereby anandamide acts on peripheral CB1 receptors located on the sensory nerve terminals of the gut to create its hyperphagic effect (51). Furthermore, experimental evidence on adipose tissue has shown that, in addition to CB1 receptors, enzymes regulating the biosynthesis and degradation of the endocannabinoids are present, and the levels of endocannabinoids in adipose tissue were found to be similar to those of the brain (52). This is probably due to an increase in the fat oxidation rate. First, this is supported by a reduction in the respiratory quotient. Secondly, experiments in adipocytic cultures have shown that chronic CB1 blockade reduces adipose mass by increasing oxidation rate, via the induction of enzymes of β-oxidation and the Krebs cycle (53). Thirdly, in the opposite situation, adipocyte cultures treated with cannabinoid agonists show lipoprotein lipase activation (2) and decreased expression of adiponectin (54), which cause triglyceride re-esterification and reduce fatty acid oxidation. Most of these effects can be explained by the inhibitory effect of cannabinoids on liver and adipose tissue AMPK activity (23). Osei-Hyiaman et al. investigated the role of the liver as a target for the peripheral regulation of energy metabolism by the endocannabinoids. When given a high-fat diet, the density of CB1 receptors increased, as did levels of hepatic anandamide. Upon activation, de novo fatty acid synthesis occurred (48) due to an increase in fatty acid synthase and acetyl-CoA carboxylase, thus promoting insulin resistance and hepatic steatosis (55). Treatment with a CB1 antagonist has been shown to reduce hepatic steatosis in rats (56), while results of treatment with rimonabant for non-alcoholic fatty liver disease in humans have been promising (57).

Hyperactivity of the endocannabinoid system in obesity

Both animal and human data show that the endocannabinoid system is up-regulated in obesity (58). A significantly higher amount of 2-AG was found in visceral fat in obese and overweight individuals when compared with normal-weight controls (54). A study on obese, postmenopausal women showed raised 2-AG and anandamide levels, along with reduced fatty acid amide hydrolase (FAAH) expression compared with control subjects (59), suggesting that impaired degradation of endocannabinoids could play a role. Further data to support the importance of endocannabinoid degradation showed that a missense polymorphism in FAAH was found to correlate with body mass index (BMI) in obese patients (60). Those with the polymorphism had only half the FAAH enzymatic activity of controls, thus providing substantial evidence for an upregulation of the endocannabinoid system in obesity due to, at least in part, a defect in the mechanism of degradation (60). However, these data were not reproduced in a similar study, which included over 5000 patients (61). Polymorphisms of the CNR1 gene encoding the CB1 receptor have also been shown to be associated with obesity (62).

Manipulating the system

The hyperactive endocannabinoid system in obesity has been targeted, using CB1 receptor antagonists, in an attempt to attenuate endocannabinoid signalling. Animal studies have shown that by blocking the CB1 receptor, both food intake and weight are significantly reduced (22, 49, 63, 64). Following on from these promising results, Sanofi-Aventis commenced human clinical trials to test the safety and efficacy of rimonabant in the treatment of obesity (65). The rimonabant in obesity (RIO) trials, with over 6600 participants, composed of four separate trials: RIO North America (66), RIO Europe (67), RIO Diabetes (68) and RIO Lipids (69), all published in distinguished journals. Inclusion criteria for the RIO Europe and RIO North America trials included a BMI >30 kg/m2 or a BMI >27 kg/m2 with obesity-induced disease (66, 67). The RIO Lipids trial involved hyperlipidaemic, overweight and obese participants who had previously had no medical therapy, while the RIO Diabetes trial included type 2 diabetic patients on monotherapy, who were also overweight or obese. At 1-year follow-up, the results of the randomised, double-blind, placebo-controlled trials showed a placebo-corrected weight loss of 4.7 kg (range 4.1–5.4) in the 20 mg group in RIO North America and 4.8 kg (3.9–5.7) in RIO Europe. RIO Lipids reported a weight loss of 5.4 kg (4.6–6.3), and RIO Diabetes result was 3.9 kg (3.2–4.6) (66, 67, 68, 69). Furthermore, HbA1c and triglyceride levels decreased, while high density lipoprotein cholesterol increased. Waist circumference was also measured in the RIO trials and resulted in statistically significant reductions in the 20 mg groups (6.1, 6.5, 7.1 and 5.2 cm respectively) compared with placebo (2.5, 2.4, 2.4 and 1.9 cm respectively). Further studies commenced including type 2 diabetic patients with no previous drug treatment (70), patients on established diabetic treatment and patients with cardiovascular risks factors were specifically followed. These studies also resulted in positive outcomes (71). The data suggested that rimonabant was a promising agent, and thus it was licensed in the European Union (EU) as an anti-obesity drug and approved by National Institute for Health and Clinical Excellence for use in the UK. Its indications were as an adjunct to a healthy diet and exercise in obese patients (BMI >30 kg/m2) and for overweight adults (BMI >27 kg/m2) with associated risk factors, such as type 2 diabetes or dyslipidaemia (NICE: National Institute for Health and Clinical Excellence: Rimonabant for the treatment of overweight and obese patients: http://www.nice.org.uk 2007).

However, a high incidence of adverse effects was reported in the RIO trials’ 20 mg groups. The most common side effects reported were headache, nausea, anxiety and depressed mood (69). Withdrawal rates were 15.0, 14.5, 12.8 and 15.0% respectively in the four trials, compared with placebo withdrawal rates of 7.0, 9.2, 7.2 and 5.5% (72). Because of the psychotropic nature of cannabis, psychiatric side effects are biologically plausible, and indeed 26% of participants in the 20 mg groups reported psychiatric symptoms. These included depression, anxiety, sleep disorders and suicidal ideation (70). However, data suggest that in real-life clinical practice, ∼50% of individuals seeking treatment for obesity also suffer from depression, making it hard to ascertain whether or not reports of depression were attributable to the drug or not (73, 74).

As a result of the psychiatric side effect profile, the US Food and Drug Administration declined permission for rimonabant, and in October 2008, rimonabant was also suspended across the EU. The European Medicines Agency (EMEA) disputed its psychiatric safety, due to an increased risk of depression and significant suicide risk. Their analysis showed an approximately doubled risk of psychiatric disorders, including depression, anxiety, sleep disturbance and suicidal ideation, in those taking rimonabant when compared with placebo. Since the withdrawal of rimonabant, other CB1 antagonist drugs have also been halted in the process of development. Taranabant (Merck & Co.) has been shown to induce chronic weight loss in diet-induced obese rats (75, 76). In a human trial, treatment with 12 mg taranabant resulted in a significant increase in resting energy expenditure, most likely due to an increase in the fat oxidation rate, supported by a reduction in the respiratory quotient when taking the drug (77). Although the drug reached phase-III human obesity trials, they were stopped in October 2008, due to a high level of central side effects, including anxiety and depression (EMEA. The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia: http://www.emea.europa.eu 2008).

Rimonabant has high affinity binding for the CB1 receptor and acts as a full inverse agonist. An alternative would be the use of a partial agonist, which would decrease cannabinoid receptor activation as well as preventing the psychiatric side effects evident when completely blocking CB1 (78). Partial agonists are reported to have a lower prevalence of adverse effects than either antagonists or inverse agonists, without reducing the efficacy of the drug (79). An example of such a drug with the potential for an anti-obesity effect is the 5-HT6 ligand, E-6837 (80). The use of partial agonists at pharmacological targets in the endocannabinoid system may produce the significant weight loss results of the cannabinoid antagonists, but without the psychiatric side effects. Data is available on a neutral CB1 cannabinoid antagonist, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4,-triazole-LH21 (81). Its lack of inverse agonist properties and low permeation of the blood–brain barrier resulted in an improved side-effect profile when compared with inverse agonists.

Conclusion

The hyperactive endocannabinoid system established in obesity has been supported with strong evidence from both animal and human experiments, with the argument for a genetic basis especially interesting. Breaking down the system and blocking the endocannabinoid pathway at any level could potentially diminish its excessive activity and promote weight loss. The peripheral actions of the system are intriguing, and selectively blocking the peripheral receptors may hold the solution to preventing the central side effects, which thus far have led to the downfall of the cannabinoid antagonists in therapeutic medicine. However, it is currently unclear whether the beneficial effects on weight, as well as lipid and carbohydrate metabolism, would be upheld in this case, as convincing data of direct central regulation of peripheral metabolism are emerging.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by the Wellcome Trust (081922/Z/07/Z).

References

  • 1

    PiomelliD. The endocannabinoid system: a drug discovery perspective. Current Opinion in Investigational Drugs20056672679.

  • 2

    CotaDMarsicanoGTschopMGrublerYFlachskammCSchubertMAuerDYassouridisAThone-ReinekeCOrtmannSTomassoniFCervinoCNisoliELinthorstACPasqualiRLutzBStallaGKPagottoU. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. Journal of Clinical Investigation2003112423431.

  • 3

    DuffyDRaderD. Endocannabinoid antagonism: blocking the excess in the treatment of high-risk abdominal obesity. Trends in Cardiovascular Medicine2007173543.

  • 4

    PerkinsJMDavisSN. Endocannabinoid system overactivity and the metabolic syndrome: prospects for treatment. Current Diabetes Reports200881219.

  • 5

    PatonWD. Cannabis and its problems. Proceedings of the Royal Society of Medicine197366718721.

  • 6

    ZiasJStarkHSellgmanJLevyRWerkerEBreuerAMechoulamR. Early medical use of cannabis. Nature1993363215.

  • 7

    GaoniYMechoulamR. The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. Journal of the American Chemical Society197193217224.

  • 8

    MatsudaLALolaitSJBrownsteinMJYoungACBonnerTI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature1990346561564.

  • 9

    MunroSThomasKLAbu-ShaarM. Molecular characterization of a peripheral receptor for cannabinoids. Nature19933656165.

  • 10

    HowlettACBarthFBonnerTICabralGCasellasPDevaneWAFelderCCHerkenhamMMackieKMartinBRMechoulamRPertweeRG. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews200254161202.

  • 11

    PertweeRG. The pharmacology of cannabinoid receptors and their ligands: an overview. International Journal of Obesity200630S13S18.

  • 12

    WittmannGDeliLKalloIHrabovszkyEWatanabeMLipositsZFeketeC. Distribution of type 1 cannabinoid receptor (CB1)-immunoreactive axons in the mouse hypothalamus. Journal of Comparative Neurology2007503270279.

  • 13

    Van SickleMDDuncanMKingsleyPJMouihateAUrbaniPMackieKStellaNMakriyannisAPiomelliDDavisonJSMarnettLJDi MarzoVPittmanQJPatelKDSharkeyKA. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science2005310329332.

  • 14

    PacherPBatkaiSKunosG. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews200658389462.

  • 15

    PagottoUMarsicanoGCotaDLutzBPasqualiR. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrine Reviews20062773100.

  • 16

    HowlettACBreivogelCSChildersSRDeadwylerSAHampsonREPorrinoLJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology200447345358.

  • 17

    ZygmuntPMPeterssonJAnderssonDAChuangHSorgardMDi MarzoVJuliusDHogestattED. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature1999400452457.

  • 18

    RybergELarssonNSjogrenSHjorthSHermanssonNOLeonovaJElebringTNilssonKDrmotaTGreasleyPJ. The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology200715210921101.

  • 19

    PacherPBatkaiSKunosG. Blood pressure regulation by endocannabinoids and their receptors. Neuropharmacology20054811301138.

  • 20

    O'SullivanSEKendallDARandallMD. Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA). British Journal of Pharmacology2004141803812.

  • 21

    WilliamsCMKirkhamTC. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology1999143315317.

  • 22

    JamshidiNTaylorDA. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. British Journal of Pharmacology200113411511154.

  • 23

    KolaBHubinaETucciSAKirkhamTCGarciaEAMitchellSEWilliamsLMHawleySAHardieDGGrossmanABKorbonitsM. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. Journal of Biological Chemistry20052802519625201.

  • 24

    KolaB. Role of AMP-activated protein kinase in the control of appetite. Journal of Neuroendocrinology200820942951.

  • 25

    EllisJPedianiJDCanalsMMilastaSMilliganG. Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. Journal of Biological Chemistry20062813881238824.

  • 26

    KearnCSBlake-PalmerKDanielEMackieKGlassM. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk?Molecular Pharmacology20056716971704.

  • 27

    HojoMSudoYAndoYMinamiKTakadaMMatsubaraTKanaideMTaniyamaKSumikawaKUezonoY. mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. Journal of Pharmacological Sciences2008108308319.

  • 28

    KolaBFarkasIChrist-CrainMWittmannGLolliFAminFHarvey-WhiteJLipositsZKunosGGrossmanABFeketeCKorbonitsM. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS ONE20083e1797.

  • 29

    HermannHMarsicanoGLutzB. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience2002109451460.

  • 30

    WatanabeTKubotaNOhsugiMKubotaTTakamotoIIwabuMAwazawaMKatsuyamaHHasegawaCTokuyamaKMoroiMSugiKYamauchiTNodaTNagaiRTerauchiYTobeKUekiKKadowakiT. Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways. Journal of Biological Chemistry200928418031812.

  • 31

    MonteleonePMatiasIMartiadisVDe PetrocellisLMajMDi MarzoV. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology20053012161221.

  • 32

    MaccarroneMFrideEBisognoTBariMCascioMGBattistaNFinazzi AgroASurisRMechoulamRDi MarzoV. Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. Molecular Human Reproduction2005112128.

  • 33

    Di MarzoVGoparajuSKWangLLiuJBatkaiSJaraiZFezzaFMiuraGIPalmiterRDSugiuraTKunosG. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature2001410822825.

  • 34

    BensaidMGary-BoboMEsclangonAMaffrandJPLe FurGOury-DonatFSoubrieP. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Molecular Pharmacology200363908914.

  • 35

    GamberKMMacarthurHWestfallTC. Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus. Neuropharmacology200549646652.

  • 36

    VertyANMcFarlaneJRMcGregorISMalletPE. Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology200414532243231.

  • 37

    HilairetSBouaboulaMCarriereDLe FurGCasellasP. Hypersensitization of the orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. Journal of Biological Chemistry20032782373123737.

  • 38

    DiSMalcher-LopesRHalmosKCTaskerJG. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. Journal of Neuroscience20032348504857.

  • 39

    DiSMalcher-LopesRMarcheselliVLBazanNGTaskerJG. Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and gamma-aminobutyric acid inputs to hypothalamic magnocellular neurons. Endocrinology200514642924301.

  • 40

    MarsicanoGLutzB. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. European Journal of Neuroscience19991142134225.

  • 41

    MelisTSuccuSSannaFBoiAArgiolasAMelisMR. The cannabinoid antagonist SR 141716A (rimonabant) reduces the increase of extra-cellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food. Neuroscience Letters2007419231235.

  • 42

    GerardCMMollereauCVassartGParmentierM. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochemical Journal1991279129134.

  • 43

    CrociTManaraLAureggiGGuagniniFRinaldi-CarmonaMMaffrandJPLe FurGMukengeSFerlaG. In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. British Journal of Pharmacology199812513931395.

  • 44

    Osei-HyiamanDLiuJZhouLGodlewskiGHarvey-WhiteJJeongWIBatkaiSMarsicanoGLutzBBuettnerCKunosG. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. Journal of Clinical Investigation200811831603169.

  • 45

    LiuYLConnoleyIPWilsonCAStockMJ. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. International Journal of Obesity200529183187.

  • 46

    Juan-PicoPFuentesEBermudez-SilvaFJJavier Diaz-MolinaFRipollCRodriguez de FonsecaFNadalA. Cannabinoid receptors regulate Ca (2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium200639155162.

  • 47

    DespresJP. The endocannabinoid system: a new target for the regulation of energy balance and metabolism. Critical Pathways in Cardiology200764650.

  • 48

    Osei-HyiamanDDePetrilloMPacherPLiuJRadaevaSBatkaiSHarvey-WhiteJMackieKOffertalerLWangLKunosG. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. Journal of Clinical Investigation200511512981305.

  • 49

    Ravinet TrillouCArnoneMDelgorgeCGonalonsNKeanePMaffrandJPSoubrieP. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. American Journal of Physiology. Regulatory Integrative and Comparative Physiology2003284R345R353.

  • 50

    GreenbergIKuehnleJMendelsonJHBernsteinJG. Effects of marihuana use on body weight and caloric intake in humans. Psychopharmacology1976497984.

  • 51

    GomezRNavarroMFerrerBTrigoJMBilbaoADel ArcoICippitelliANavaFPiomelliDRodriguez de FonsecaF. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. Journal of Neuroscience20022296129617.

  • 52

    PaganoCPilonCCalcagnoAUrbanetRRossatoMMilanGBianchiKRizzutoRBernantePFederspilGVettorR. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. Journal of Clinical Endocrinology and Metabolism20079248104819.

  • 53

    JbiloORavinet-TrillouCArnoneMBuissonIBribesEPelerauxAPenarierGSoubriePLe FurGGaliegueSCasellasP. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB Journal20051915671569.

  • 54

    MatiasIGonthierMPOrlandoPMartiadisVDe PetrocellisLCervinoCPetrosinoSHoareauLFestyFPasqualiRRocheRMajMPagottoUMonteleonePDi MarzoV. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. Journal of Clinical Endocrinology and Metabolism20069131713180.

  • 55

    JesudasonDWittertG. Endocannabinoid system in food intake and metabolic regulation. Current Opinion in Lipidology200819344348.

  • 56

    Gary-BoboMElachouriGGallasJFJaniakPMariniPRavinet-TrillouCChabbertMCruccioliNPfersdorffCRoqueCArnoneMCrociTSoubriePOury-DonatFMaffrandJPScattonBLacheretzFLe FurGHerbertJMBensaidM. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology200746122129.

  • 57

    BanaschMGoetzeOSchmidtWEMeierJJ. Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis. Liver International20072711521155.

  • 58

    Di MarzoVMatiasI. Endocannabinoid control of food intake and energy balance. Nature Neuroscience20058585589.

  • 59

    EngeliSBohnkeJFeldpauschMGorzelniakKJankeJBatkaiSPacherPHarvey-WhiteJLuftFCSharmaAMJordanJ. Activation of the peripheral endocannabinoid system in human obesity. Diabetes20055428382843.

  • 60

    SipeJCWaalenJGerberABeutlerE. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). International Journal of Obesity200529755759.

  • 61

    JensenDPAndreasenCHAndersenMKHansenLEibergHBorch-JohnsenKJorgensenTHansenTPedersenO. The functional Pro129Thr variant of the FAAH gene is not associated with various fat accumulation phenotypes in a population-based cohort of 5,801 whites. Journal of Molecular Medicine200785445449.

  • 62

    RussoPStrazzulloPCappuccioFPTregouetDALauriaFLoguercioMBarbaGVersieroMSianiA. Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men. Journal of Clinical Endocrinology and Metabolism20079223822386.

  • 63

    ArnoneMMaruaniJChaperonFThiebotMHPonceletMSoubriePLe FurG. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology1997132104106.

  • 64

    SimiandJKeaneMKeanePESoubrieP. SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behavioural Pharmacology19989179181.

  • 65

    Rinaldi-CarmonaMBarthFHeaulmeMShireDCalandraBCongyCMartinezSMaruaniJNeliatGCaputDNeliatGArnoneMFinanceOSoubriePLe FurG. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters1994350240244.

  • 66

    Pi-SunyerFXAronneLJHeshmatiHMDevinJRosenstockJ. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. Journal of the American Medical Association2006295761775.

  • 67

    Van GaalLFRissanenAMScheenAJZieglerORossnerS. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet200536513891397.

  • 68

    ScheenAJFinerNHollanderPJensenMDVan GaalLF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet200636816601672.

  • 69

    DespresJPGolayASjostromL. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New England Journal of Medicine200535321212134.

  • 70

    NissenSENichollsSJWolskiKRodes-CabauJCannonCPDeanfieldJEDespresJPKasteleinJJSteinhublSRKapadiaSYasinMRuzylloWGaudinCJobBHuBBhattDLLincoffAMTuzcuEM. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. Journal of the American Medical Association200829915471560.

  • 71

    ScheenAJPaquotN. Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. Best Practice & Research. Clinical Endocrinology & Metabolism200923103116.

  • 72

    CurioniCAndreC. Rimonabant for overweight or obesity. Cochrane Database of Systematic Reviews2006Issue 4 CD006162.

  • 73

    ChristensenRKristensenPKBartelsEMBliddalHAstrupA. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet200737017061713.

  • 74

    ClelandSJSattarN. Does rimonabant pull its weight for type 2 diabetes?Lancet200636816321634.

  • 75

    LinLSLanzaTJJrJewellJPLiuPShahSKQiHTongXWangJXuSSFongTMShenCPLaoJXiaoJCShearmanLPStriblingDSRoskoKStrackAMarshDJFengYKumarSSamuelKYinWVan der PloegLHGouletMTHagmannWK. Discovery of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. Journal of Medicinal Chemistry20064975847587.

  • 76

    FongTMGuanXMMarshDJShenCPStriblingDSRoskoKMLaoJYuHFengYXiaoJCVan der PloegLHGouletMTHagmannWKLinLSLanzaTJJrJewellJPLiuPShahSKQiHTongXWangJXuSSFrancisBStrackAMMacIntyreDEShearmanLP. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents. Journal of Pharmacology and Experimental Therapeutics200732110131022.

  • 77

    AddyCWrightHVan LaereKGantzIEronduNMusserBJLuKYuanJSanabria-BohorquezSMStochAStevensCFongTMDe LepeleireICilissenCCoteJRoskoKGendranoINIIINguyenAMGumbinerBRothenbergPde HoonJBormansGDepreMEngWSRavussinEKleinSBlundellJHermanGABurnsHDHargreavesRJWagnerJGottesdienerKAmatrudaJMHeymsfieldSB. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metabolism200876878.

  • 78

    ViverosMPde FonsecaFRBermudez-SilvaFJMcPartlandJM. Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications. Endocrine Metabolic & Immune Disorders Drug Targets20088220230.

  • 79

    OhlsenRIPilowskyLS. The place of partial agonism in psychiatry: recent developments. Journal of Psychopharmacology200519408413.

  • 80

    FisasACodonyXRomeroGDordalAGiraldoJMerceRHolenzJVrangNSorensenRVHealDBuschmannHPauwelsPJ. Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats. British Journal of Pharmacology2006148973983.

  • 81

    PavonFJBilbaoAHernandez-FolgadoLCippitelliAJagerovicNAbellanGRodriguez-FrancoMASerranoAMaciasMGomezRNavarroMGoyaPRodriguez de FonsecaF. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole – LH 21. Neuropharmacology200651358366.

  • 82

    Christ-CrainMKolaBLolliFFeketeCSeboekDWittmannGFeltrinDIgrejaSCAjodhaSHarvey-WhiteJKunosGMullerBPralongFAubertGArnaldiGGiacchettiGBoscaroMGrossmanABKorbonitsM. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB Journal20082216721683.

  • 83

    OkamotoYMorishitaJTsuboiKTonaiTUedaN. Molecular characterization of a phospholipase D generating anandamide and its congeners. Journal of Biological Chemistry200427952985305.

  • 84

    TsouKNogueronMIMuthianSSanudo-PenaMCHillardCJDeutschDGWalkerJM. Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. Neuroscience Letters1998254137140.

If the inline PDF is not rendering correctly, you can download the PDF file here.

 

     European Society of Endocrinology

Related Articles

Article Information

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 387 387 34
PDF Downloads 86 86 11

Altmetrics

Figures

  • View in gallery

    Upon stimulation of the postsynaptic cell, an influx of intracellular calcium results in the activation of N-acylphosphatidylethamolamine hydrolysing phospholipase D (NAPE–PLD) and diacyl–glycerol lipase (DAGL-α and -β) and release of endocannabinoids (e.g. anandamide (ANA) or 2-arachidonoylglycerol (2-AG)) from the postsynaptic terminal. The endocannabinoid crosses the synaptic cleft and binds to its receptor on the presynaptic terminal. Cannabinoid receptor activation often results in blocked neurotransmitter release from the presynaptic neuron. The endocannabinoids are taken up by the postsynaptic cell via a method of unspecified transport (green crescents) and are finally inactivated and degraded by fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL) (83, 84).

  • View in gallery

    Cannabinoid receptor activation often leads to reduced cellular neurotransmission by blocking Ca2+ entry, via hyperpolarisation, as a result of K+ channel activation, or by reduced cAMP generation.

References

1

PiomelliD. The endocannabinoid system: a drug discovery perspective. Current Opinion in Investigational Drugs20056672679.

2

CotaDMarsicanoGTschopMGrublerYFlachskammCSchubertMAuerDYassouridisAThone-ReinekeCOrtmannSTomassoniFCervinoCNisoliELinthorstACPasqualiRLutzBStallaGKPagottoU. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. Journal of Clinical Investigation2003112423431.

3

DuffyDRaderD. Endocannabinoid antagonism: blocking the excess in the treatment of high-risk abdominal obesity. Trends in Cardiovascular Medicine2007173543.

4

PerkinsJMDavisSN. Endocannabinoid system overactivity and the metabolic syndrome: prospects for treatment. Current Diabetes Reports200881219.

5

PatonWD. Cannabis and its problems. Proceedings of the Royal Society of Medicine197366718721.

6

ZiasJStarkHSellgmanJLevyRWerkerEBreuerAMechoulamR. Early medical use of cannabis. Nature1993363215.

7

GaoniYMechoulamR. The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. Journal of the American Chemical Society197193217224.

8

MatsudaLALolaitSJBrownsteinMJYoungACBonnerTI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature1990346561564.

9

MunroSThomasKLAbu-ShaarM. Molecular characterization of a peripheral receptor for cannabinoids. Nature19933656165.

10

HowlettACBarthFBonnerTICabralGCasellasPDevaneWAFelderCCHerkenhamMMackieKMartinBRMechoulamRPertweeRG. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews200254161202.

11

PertweeRG. The pharmacology of cannabinoid receptors and their ligands: an overview. International Journal of Obesity200630S13S18.

12

WittmannGDeliLKalloIHrabovszkyEWatanabeMLipositsZFeketeC. Distribution of type 1 cannabinoid receptor (CB1)-immunoreactive axons in the mouse hypothalamus. Journal of Comparative Neurology2007503270279.

13

Van SickleMDDuncanMKingsleyPJMouihateAUrbaniPMackieKStellaNMakriyannisAPiomelliDDavisonJSMarnettLJDi MarzoVPittmanQJPatelKDSharkeyKA. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science2005310329332.

14

PacherPBatkaiSKunosG. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews200658389462.

15

PagottoUMarsicanoGCotaDLutzBPasqualiR. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrine Reviews20062773100.

16

HowlettACBreivogelCSChildersSRDeadwylerSAHampsonREPorrinoLJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology200447345358.

17

ZygmuntPMPeterssonJAnderssonDAChuangHSorgardMDi MarzoVJuliusDHogestattED. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature1999400452457.

18

RybergELarssonNSjogrenSHjorthSHermanssonNOLeonovaJElebringTNilssonKDrmotaTGreasleyPJ. The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology200715210921101.

19

PacherPBatkaiSKunosG. Blood pressure regulation by endocannabinoids and their receptors. Neuropharmacology20054811301138.

20

O'SullivanSEKendallDARandallMD. Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA). British Journal of Pharmacology2004141803812.

21

WilliamsCMKirkhamTC. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology1999143315317.

22

JamshidiNTaylorDA. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. British Journal of Pharmacology200113411511154.

23

KolaBHubinaETucciSAKirkhamTCGarciaEAMitchellSEWilliamsLMHawleySAHardieDGGrossmanABKorbonitsM. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. Journal of Biological Chemistry20052802519625201.

24

KolaB. Role of AMP-activated protein kinase in the control of appetite. Journal of Neuroendocrinology200820942951.

25

EllisJPedianiJDCanalsMMilastaSMilliganG. Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. Journal of Biological Chemistry20062813881238824.

26

KearnCSBlake-PalmerKDanielEMackieKGlassM. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk?Molecular Pharmacology20056716971704.

27

HojoMSudoYAndoYMinamiKTakadaMMatsubaraTKanaideMTaniyamaKSumikawaKUezonoY. mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. Journal of Pharmacological Sciences2008108308319.

28

KolaBFarkasIChrist-CrainMWittmannGLolliFAminFHarvey-WhiteJLipositsZKunosGGrossmanABFeketeCKorbonitsM. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS ONE20083e1797.

29

HermannHMarsicanoGLutzB. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience2002109451460.

30

WatanabeTKubotaNOhsugiMKubotaTTakamotoIIwabuMAwazawaMKatsuyamaHHasegawaCTokuyamaKMoroiMSugiKYamauchiTNodaTNagaiRTerauchiYTobeKUekiKKadowakiT. Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways. Journal of Biological Chemistry200928418031812.

31

MonteleonePMatiasIMartiadisVDe PetrocellisLMajMDi MarzoV. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology20053012161221.

32

MaccarroneMFrideEBisognoTBariMCascioMGBattistaNFinazzi AgroASurisRMechoulamRDi MarzoV. Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. Molecular Human Reproduction2005112128.

33

Di MarzoVGoparajuSKWangLLiuJBatkaiSJaraiZFezzaFMiuraGIPalmiterRDSugiuraTKunosG. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature2001410822825.

34

BensaidMGary-BoboMEsclangonAMaffrandJPLe FurGOury-DonatFSoubrieP. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Molecular Pharmacology200363908914.

35

GamberKMMacarthurHWestfallTC. Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus. Neuropharmacology200549646652.

36

VertyANMcFarlaneJRMcGregorISMalletPE. Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology200414532243231.

37

HilairetSBouaboulaMCarriereDLe FurGCasellasP. Hypersensitization of the orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. Journal of Biological Chemistry20032782373123737.

38

DiSMalcher-LopesRHalmosKCTaskerJG. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. Journal of Neuroscience20032348504857.

39

DiSMalcher-LopesRMarcheselliVLBazanNGTaskerJG. Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and gamma-aminobutyric acid inputs to hypothalamic magnocellular neurons. Endocrinology200514642924301.

40

MarsicanoGLutzB. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. European Journal of Neuroscience19991142134225.

41

MelisTSuccuSSannaFBoiAArgiolasAMelisMR. The cannabinoid antagonist SR 141716A (rimonabant) reduces the increase of extra-cellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food. Neuroscience Letters2007419231235.

42

GerardCMMollereauCVassartGParmentierM. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochemical Journal1991279129134.

43

CrociTManaraLAureggiGGuagniniFRinaldi-CarmonaMMaffrandJPLe FurGMukengeSFerlaG. In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. British Journal of Pharmacology199812513931395.

44

Osei-HyiamanDLiuJZhouLGodlewskiGHarvey-WhiteJJeongWIBatkaiSMarsicanoGLutzBBuettnerCKunosG. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. Journal of Clinical Investigation200811831603169.

45

LiuYLConnoleyIPWilsonCAStockMJ. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. International Journal of Obesity200529183187.

46

Juan-PicoPFuentesEBermudez-SilvaFJJavier Diaz-MolinaFRipollCRodriguez de FonsecaFNadalA. Cannabinoid receptors regulate Ca (2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium200639155162.

47

DespresJP. The endocannabinoid system: a new target for the regulation of energy balance and metabolism. Critical Pathways in Cardiology200764650.

48

Osei-HyiamanDDePetrilloMPacherPLiuJRadaevaSBatkaiSHarvey-WhiteJMackieKOffertalerLWangLKunosG. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. Journal of Clinical Investigation200511512981305.

49

Ravinet TrillouCArnoneMDelgorgeCGonalonsNKeanePMaffrandJPSoubrieP. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. American Journal of Physiology. Regulatory Integrative and Comparative Physiology2003284R345R353.

50

GreenbergIKuehnleJMendelsonJHBernsteinJG. Effects of marihuana use on body weight and caloric intake in humans. Psychopharmacology1976497984.

51

GomezRNavarroMFerrerBTrigoJMBilbaoADel ArcoICippitelliANavaFPiomelliDRodriguez de FonsecaF. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. Journal of Neuroscience20022296129617.

52

PaganoCPilonCCalcagnoAUrbanetRRossatoMMilanGBianchiKRizzutoRBernantePFederspilGVettorR. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. Journal of Clinical Endocrinology and Metabolism20079248104819.

53

JbiloORavinet-TrillouCArnoneMBuissonIBribesEPelerauxAPenarierGSoubriePLe FurGGaliegueSCasellasP. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB Journal20051915671569.

54

MatiasIGonthierMPOrlandoPMartiadisVDe PetrocellisLCervinoCPetrosinoSHoareauLFestyFPasqualiRRocheRMajMPagottoUMonteleonePDi MarzoV. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. Journal of Clinical Endocrinology and Metabolism20069131713180.

55

JesudasonDWittertG. Endocannabinoid system in food intake and metabolic regulation. Current Opinion in Lipidology200819344348.

56

Gary-BoboMElachouriGGallasJFJaniakPMariniPRavinet-TrillouCChabbertMCruccioliNPfersdorffCRoqueCArnoneMCrociTSoubriePOury-DonatFMaffrandJPScattonBLacheretzFLe FurGHerbertJMBensaidM. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology200746122129.

57

BanaschMGoetzeOSchmidtWEMeierJJ. Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis. Liver International20072711521155.

58

Di MarzoVMatiasI. Endocannabinoid control of food intake and energy balance. Nature Neuroscience20058585589.

59

EngeliSBohnkeJFeldpauschMGorzelniakKJankeJBatkaiSPacherPHarvey-WhiteJLuftFCSharmaAMJordanJ. Activation of the peripheral endocannabinoid system in human obesity. Diabetes20055428382843.

60

SipeJCWaalenJGerberABeutlerE. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). International Journal of Obesity200529755759.

61

JensenDPAndreasenCHAndersenMKHansenLEibergHBorch-JohnsenKJorgensenTHansenTPedersenO. The functional Pro129Thr variant of the FAAH gene is not associated with various fat accumulation phenotypes in a population-based cohort of 5,801 whites. Journal of Molecular Medicine200785445449.

62

RussoPStrazzulloPCappuccioFPTregouetDALauriaFLoguercioMBarbaGVersieroMSianiA. Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men. Journal of Clinical Endocrinology and Metabolism20079223822386.

63

ArnoneMMaruaniJChaperonFThiebotMHPonceletMSoubriePLe FurG. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology1997132104106.

64

SimiandJKeaneMKeanePESoubrieP. SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behavioural Pharmacology19989179181.

65

Rinaldi-CarmonaMBarthFHeaulmeMShireDCalandraBCongyCMartinezSMaruaniJNeliatGCaputDNeliatGArnoneMFinanceOSoubriePLe FurG. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters1994350240244.

66

Pi-SunyerFXAronneLJHeshmatiHMDevinJRosenstockJ. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. Journal of the American Medical Association2006295761775.

67

Van GaalLFRissanenAMScheenAJZieglerORossnerS. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet200536513891397.

68

ScheenAJFinerNHollanderPJensenMDVan GaalLF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet200636816601672.

69

DespresJPGolayASjostromL. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New England Journal of Medicine200535321212134.

70

NissenSENichollsSJWolskiKRodes-CabauJCannonCPDeanfieldJEDespresJPKasteleinJJSteinhublSRKapadiaSYasinMRuzylloWGaudinCJobBHuBBhattDLLincoffAMTuzcuEM. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. Journal of the American Medical Association200829915471560.

71

ScheenAJPaquotN. Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. Best Practice & Research. Clinical Endocrinology & Metabolism200923103116.

72

CurioniCAndreC. Rimonabant for overweight or obesity. Cochrane Database of Systematic Reviews2006Issue 4 CD006162.

73

ChristensenRKristensenPKBartelsEMBliddalHAstrupA. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet200737017061713.

74

ClelandSJSattarN. Does rimonabant pull its weight for type 2 diabetes?Lancet200636816321634.

75

LinLSLanzaTJJrJewellJPLiuPShahSKQiHTongXWangJXuSSFongTMShenCPLaoJXiaoJCShearmanLPStriblingDSRoskoKStrackAMarshDJFengYKumarSSamuelKYinWVan der PloegLHGouletMTHagmannWK. Discovery of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. Journal of Medicinal Chemistry20064975847587.

76

FongTMGuanXMMarshDJShenCPStriblingDSRoskoKMLaoJYuHFengYXiaoJCVan der PloegLHGouletMTHagmannWKLinLSLanzaTJJrJewellJPLiuPShahSKQiHTongXWangJXuSSFrancisBStrackAMMacIntyreDEShearmanLP. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents. Journal of Pharmacology and Experimental Therapeutics200732110131022.

77

AddyCWrightHVan LaereKGantzIEronduNMusserBJLuKYuanJSanabria-BohorquezSMStochAStevensCFongTMDe LepeleireICilissenCCoteJRoskoKGendranoINIIINguyenAMGumbinerBRothenbergPde HoonJBormansGDepreMEngWSRavussinEKleinSBlundellJHermanGABurnsHDHargreavesRJWagnerJGottesdienerKAmatrudaJMHeymsfieldSB. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metabolism200876878.

78

ViverosMPde FonsecaFRBermudez-SilvaFJMcPartlandJM. Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications. Endocrine Metabolic & Immune Disorders Drug Targets20088220230.

79

OhlsenRIPilowskyLS. The place of partial agonism in psychiatry: recent developments. Journal of Psychopharmacology200519408413.

80

FisasACodonyXRomeroGDordalAGiraldoJMerceRHolenzJVrangNSorensenRVHealDBuschmannHPauwelsPJ. Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats. British Journal of Pharmacology2006148973983.

81

PavonFJBilbaoAHernandez-FolgadoLCippitelliAJagerovicNAbellanGRodriguez-FrancoMASerranoAMaciasMGomezRNavarroMGoyaPRodriguez de FonsecaF. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole – LH 21. Neuropharmacology200651358366.

82

Christ-CrainMKolaBLolliFFeketeCSeboekDWittmannGFeltrinDIgrejaSCAjodhaSHarvey-WhiteJKunosGMullerBPralongFAubertGArnaldiGGiacchettiGBoscaroMGrossmanABKorbonitsM. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB Journal20082216721683.

83

OkamotoYMorishitaJTsuboiKTonaiTUedaN. Molecular characterization of a phospholipase D generating anandamide and its congeners. Journal of Biological Chemistry200427952985305.

84

TsouKNogueronMIMuthianSSanudo-PenaMCHillardCJDeutschDGWalkerJM. Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. Neuroscience Letters1998254137140.

Cited By

PubMed

Google Scholar